Shambavi Richard, MDVideo Insights | March 24, 2023
Shambavi Richard, discusses a retrospective study on extramedullary disease and CAR-T in multiple myeloma.
View More
Simona Soverini, PhDVideo Insights | January 10, 2023
Simona Soverini, PhD, discusses new molecular data on CML, remaining challenges, and potentially practice-changing data.
Sarah Tasian, MDVideo Insights | January 10, 2023
Sarah Tasian, MD, of the Children's Hospital of Philadelphia, talks with The HemOnc Pulse about pediatric oncology.
Cecilia BrownAggressive B-Cell Lymphoma | December 22, 2022
A simulation approach identified odronextamab dosing regimens that could be used in children with aggressive NHL.
Kerri FitzgeraldMeeting News | December 21, 2022
Race/ethnicity, income, and access to chemotherapy and radiation therapy improved outcomes in patients with Burkitt lymphoma.
Kerri FitzgeraldMeeting News | December 21, 2022
The cell of origin in patients with diffuse large B-cell lymphoma may impact their response to CAR-T therapy and survival.
Cecilia BrownMeeting News | February 1, 2023
Patients with ALL who underwent allogeneic HSCT in their first complete remission had a two-year OS rate of 73.9%.
Leah SherwoodMeeting News | December 21, 2022
Cachexia could be used as a prognostic marker for survival after CAR-T therapy in patients with aggressive B-cell lymphoma.
Leah SherwoodMeeting News | February 1, 2023
In follow-up data from the phase II CAPTIVATE study, ibrutinib plus venetoclax demonstrated a favorable benefit-risk profile.
Cecilia BrownAcute Lymphoblastic Leukemia | February 1, 2023
An asparaginase-containing, pediatric-inspired regimen led to an overall survival benefit in teens and young adults with ALL.
Cecilia BrownMeeting News | March 28, 2023
Zanubrutinib may be “more efficacious and better tolerated” than ibrutinib for patients with relapsed/refractory CLL or ...
Amy Kirkwood, MScVideo Insights | February 1, 2023
Amy Kirkwood, MSc, discusses results from the randomized phase III UKALL trial during the 2022 ASH Annual Meeting.
Jennifer R. Brown, MD, PhDChronic Lymphocytic Leukemia | February 8, 2024
SOHO President Jennifer R. Brown, MD, PhD, speaks about the phase III ALPINE study, which compared BTK inhibitors in CLL/SLL.
Leah SherwoodChronic Lymphocytic Leukemia | February 1, 2023
The CLL2-Give trial determined that obinutuzumab, ibrutinib, and venetoclax is a “potent and promising” treatment for ...
Leah SherwoodMeeting News | May 30, 2023
Srdan Verstovsek, MD, discusses using machine learning to predict resistance to hydroxyurea therapy in polycythemia vera.
Cecilia BrownChronic Lymphocytic Leukemia | February 1, 2023
Patients with chronic lymphocytic leukemia (CLL) primarily rely on their physicians for information about their disease.
Cecilia BrownMyeloproliferative Neoplasms | May 30, 2023
Patients with MPN have a high risk of death from cardiovascular causes.
Cecilia BrownMyeloproliferative Neoplasms | December 20, 2022
Patients with MPN who are employed face a “high economic burden,” especially if they experience thrombotic events.
Cecilia BrownMyeloproliferative Neoplasms | December 20, 2022
Statin use may reduce the risk of developing a myeloproliferative neoplasm (MPN), according to a recent study.
Chadi Nabhan, MD, MBA, FACPVideo Insights | January 10, 2023
Chadi Nabhan, MD, MBA, FACP, interviews Srdan Verstovsek, MD, on highlights in MPN research at the 2022 ASH Annual Meeting.
Editorial Board